REFRACTORY AUTOIMMUNE HAEMOLYTIC ANEMIA IN ELDERLY EFFECTIVELY TREATED WITH MYCOPHENOLATE MOFETIL.
(Abstract release date: 05/19/16)
EHA Library. Rouka E. 06/09/16; 135030; PB2130
Dr. Erasmia Rouka
Contributions
Contributions
Abstract
Abstract: PB2130
Type: Publication Only
Background
Autoimmune haemolytic anemia (AIH) is a rare disorder that sometimes may be lifethreatening. The treatment is not evidence based and corticosteroids, azathioprine, cyclophosphamide, rituximab, and mycophenolate mofetil have been used effectively although there is not enough evidence for the effectiveness and safety of the later one.
Aims
We present here 7 patients with AIH that were treated effectively with mycophenolate mofetil.
Methods
Seven patients, 6 males and 1 female aged 75-82 years were refered to our department diagnosed with autoimmune haemolytic anaemia 12 to 60 months ago. Three patients had received corticosteroids, azathioprine cyclophosphamide and rituximab without gaining a PR or better and without obtaining stable condition maintaining Hb levels about 9g/dl. Two patients obtained PR with costicosteroids and rituximab but relapsed within 6 months and could not get rid of the drugs for more than 4 months. The remaining 2 were on contineous corticosteroid treatment and occasionally rituximab for more than 4 years maintaining hemoglobin levels between 8 and 10 g/dl. All the patients started mycophenolate mofetin for 3 months and corticosteroid tapering thereafter.
Results
Within 6 months 6 patients reached normal levels of haemoglobin and reduced DAT titer to equal or less than half. They continued the drug for 26-36 months when DAT was negative and remained in remmision for 15-22 months without any drug. The 7th patient continues taking mycophenolate for 5 years with haematological remission (Hb=14g/dl) but DAT (+). All the patients tolerated the drug very well without major adverse events. Lymphocytopenia grade 2 and hypoglobulinaemia grade was a common condition in all patients without infections. The 7th patient was prophylactically indroduced to antiviral therapy as well as to cotrimoxazol/azathioprine.
Conclusion
Mycophenolate mofetil is an effective and well-tolerated drug in elderly patients with haemolytic anemia refractory to conventional therapies.
Session topic: E-poster
Keyword(s): Autoimmune hemolytic anemia (AIHA), Elderly
Type: Publication Only
Background
Autoimmune haemolytic anemia (AIH) is a rare disorder that sometimes may be lifethreatening. The treatment is not evidence based and corticosteroids, azathioprine, cyclophosphamide, rituximab, and mycophenolate mofetil have been used effectively although there is not enough evidence for the effectiveness and safety of the later one.
Aims
We present here 7 patients with AIH that were treated effectively with mycophenolate mofetil.
Methods
Seven patients, 6 males and 1 female aged 75-82 years were refered to our department diagnosed with autoimmune haemolytic anaemia 12 to 60 months ago. Three patients had received corticosteroids, azathioprine cyclophosphamide and rituximab without gaining a PR or better and without obtaining stable condition maintaining Hb levels about 9g/dl. Two patients obtained PR with costicosteroids and rituximab but relapsed within 6 months and could not get rid of the drugs for more than 4 months. The remaining 2 were on contineous corticosteroid treatment and occasionally rituximab for more than 4 years maintaining hemoglobin levels between 8 and 10 g/dl. All the patients started mycophenolate mofetin for 3 months and corticosteroid tapering thereafter.
Results
Within 6 months 6 patients reached normal levels of haemoglobin and reduced DAT titer to equal or less than half. They continued the drug for 26-36 months when DAT was negative and remained in remmision for 15-22 months without any drug. The 7th patient continues taking mycophenolate for 5 years with haematological remission (Hb=14g/dl) but DAT (+). All the patients tolerated the drug very well without major adverse events. Lymphocytopenia grade 2 and hypoglobulinaemia grade was a common condition in all patients without infections. The 7th patient was prophylactically indroduced to antiviral therapy as well as to cotrimoxazol/azathioprine.
Conclusion
Mycophenolate mofetil is an effective and well-tolerated drug in elderly patients with haemolytic anemia refractory to conventional therapies.
Session topic: E-poster
Keyword(s): Autoimmune hemolytic anemia (AIHA), Elderly
Abstract: PB2130
Type: Publication Only
Background
Autoimmune haemolytic anemia (AIH) is a rare disorder that sometimes may be lifethreatening. The treatment is not evidence based and corticosteroids, azathioprine, cyclophosphamide, rituximab, and mycophenolate mofetil have been used effectively although there is not enough evidence for the effectiveness and safety of the later one.
Aims
We present here 7 patients with AIH that were treated effectively with mycophenolate mofetil.
Methods
Seven patients, 6 males and 1 female aged 75-82 years were refered to our department diagnosed with autoimmune haemolytic anaemia 12 to 60 months ago. Three patients had received corticosteroids, azathioprine cyclophosphamide and rituximab without gaining a PR or better and without obtaining stable condition maintaining Hb levels about 9g/dl. Two patients obtained PR with costicosteroids and rituximab but relapsed within 6 months and could not get rid of the drugs for more than 4 months. The remaining 2 were on contineous corticosteroid treatment and occasionally rituximab for more than 4 years maintaining hemoglobin levels between 8 and 10 g/dl. All the patients started mycophenolate mofetin for 3 months and corticosteroid tapering thereafter.
Results
Within 6 months 6 patients reached normal levels of haemoglobin and reduced DAT titer to equal or less than half. They continued the drug for 26-36 months when DAT was negative and remained in remmision for 15-22 months without any drug. The 7th patient continues taking mycophenolate for 5 years with haematological remission (Hb=14g/dl) but DAT (+). All the patients tolerated the drug very well without major adverse events. Lymphocytopenia grade 2 and hypoglobulinaemia grade was a common condition in all patients without infections. The 7th patient was prophylactically indroduced to antiviral therapy as well as to cotrimoxazol/azathioprine.
Conclusion
Mycophenolate mofetil is an effective and well-tolerated drug in elderly patients with haemolytic anemia refractory to conventional therapies.
Session topic: E-poster
Keyword(s): Autoimmune hemolytic anemia (AIHA), Elderly
Type: Publication Only
Background
Autoimmune haemolytic anemia (AIH) is a rare disorder that sometimes may be lifethreatening. The treatment is not evidence based and corticosteroids, azathioprine, cyclophosphamide, rituximab, and mycophenolate mofetil have been used effectively although there is not enough evidence for the effectiveness and safety of the later one.
Aims
We present here 7 patients with AIH that were treated effectively with mycophenolate mofetil.
Methods
Seven patients, 6 males and 1 female aged 75-82 years were refered to our department diagnosed with autoimmune haemolytic anaemia 12 to 60 months ago. Three patients had received corticosteroids, azathioprine cyclophosphamide and rituximab without gaining a PR or better and without obtaining stable condition maintaining Hb levels about 9g/dl. Two patients obtained PR with costicosteroids and rituximab but relapsed within 6 months and could not get rid of the drugs for more than 4 months. The remaining 2 were on contineous corticosteroid treatment and occasionally rituximab for more than 4 years maintaining hemoglobin levels between 8 and 10 g/dl. All the patients started mycophenolate mofetin for 3 months and corticosteroid tapering thereafter.
Results
Within 6 months 6 patients reached normal levels of haemoglobin and reduced DAT titer to equal or less than half. They continued the drug for 26-36 months when DAT was negative and remained in remmision for 15-22 months without any drug. The 7th patient continues taking mycophenolate for 5 years with haematological remission (Hb=14g/dl) but DAT (+). All the patients tolerated the drug very well without major adverse events. Lymphocytopenia grade 2 and hypoglobulinaemia grade was a common condition in all patients without infections. The 7th patient was prophylactically indroduced to antiviral therapy as well as to cotrimoxazol/azathioprine.
Conclusion
Mycophenolate mofetil is an effective and well-tolerated drug in elderly patients with haemolytic anemia refractory to conventional therapies.
Session topic: E-poster
Keyword(s): Autoimmune hemolytic anemia (AIHA), Elderly
{{ help_message }}
{{filter}}